Who are Optimized Treatment (OPT)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SINECATECHINS, PODOFILOX, POLIDEXIDE SULFATE, SUTILAINS, Oral PF-07220060, Pf-08032562.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/optimized-treatment-opt.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Optimized Treatment (OPT) — Competitive Intelligence Brief

Optimized Treatment (OPT) (Optimized Treatment (OPT)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Small molecule. Area: Cardiovascular.

marketed Small molecule Unknown Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Optimized Treatment (OPT) (Optimized Treatment (OPT)) — Second Affiliated Hospital of Wenzhou Medical University. OPT is a treatment that targets the underlying cause of a specific disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Optimized Treatment (OPT) TARGET	Optimized Treatment (OPT)	Second Affiliated Hospital of Wenzhou Medical University	marketed	Small molecule	Unknown
SINECATECHINS	SINECATECHINS		marketed	Polyphenols	Unknown	2006-01-01
PODOFILOX	PODOFILOX		marketed	Topical antiviral	Unknown	1990-01-01
POLIDEXIDE SULFATE	POLIDEXIDE SULFATE		marketed	Unknown	Unknown	1974-01-01
SUTILAINS	SUTILAINS		marketed	Unknown	Unknown	1969-01-01
Oral PF-07220060	oral-pf-07220060	Pfizer	marketed	Unknown	Unknown
Pf-08032562	pf-08032562	Pfizer Inc.	marketed	unknown	unknown

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-10-02 — SINECATECHINS · 7858662 · Formulation · US

Sponsor landscape (Small molecule class)

Pfizer · 3 drugs in this class
Akorn, Inc. · 1 drug in this class
Guangdong Hengrui Pharmaceutical Co., Ltd · 1 drug in this class
Health Research, Inc. · 1 drug in this class
Imperial College London · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Nanjing Sanhome Pharmaceutical, Co., Ltd. · 1 drug in this class
Second Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
UroGen Pharma Ltd. · 1 drug in this class
Abivax S.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Optimized Treatment (OPT) — Competitive Intelligence Brief. https://druglandscape.com/ci/optimized-treatment-opt. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab